|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Select Publications
Joensuu H et al; FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354(8):809-20. Abstract
Love N; Research To Practice. Management of breast cancer in the adjuvant and
metastatic settings. Patterns of Care in Medical Oncology 2005;2(1).
Love N; Research To Practice. Management of breast cancer in the adjuvant and
metastatic settings. Patterns of Care in Medical Oncology 2005;2(3).
Piccart-Gebhart MJ et al. Trastuzumab after adjuvant chemotherapy in HER2-positive
breast cancer. N Engl J Med 2005;353(16):1659-72. Abstract
Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353(16):1673-84. Abstract
Slamon D et al. Phase III trial comparing AC-T with AC-TH and with TCH in the
adjuvant treatment of HER2 positive early breast cancer patients: Second interim
efficacy analysis. Presentation. San Antonio Breast Cancer Symposium 2006;Abstract 52.
Smith I et al; HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2- positive breast cancer: A randomised controlled trial. Lancet 2007;369(9555):29-36. Abstract
Tan-Chiu E et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23(31):7811-9. Abstract
 |
 |
